The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Impact of the addition of daratumumab to the frontline treatment of patients with AL amyloidosis
Elena Alejo, MD, PhD, University Hospital of Salamanca, Salamanca, Spain, shares insights into a retrospective study analyzing the efficacy of frontline treatment approaches in light chain (AL) amyloidosis. Dr Alejo highlights that the addition of daratumumab to proteasome inhibitors resulted in a 100% partial hematological response or better, with 75% achieving complete hematological response, significantly improving progression-free survival (PFS), even in patients with poor prognosis. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
